Dendritic Cells (DCs)-Based Cancer Immunotherapy: A Review on the Prospects of Medicinal Plants and Their Phytochemicals as Potential Pharmacological Modulators

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dendritic cells (DCs) are specialized antigen-presenting cells in humans and animals that provide antigen-specific T-cell immunity in the body. It also establishes a linkage between innate and adaptive immune responses. Various studies have shown that malignancies or cancer may impair DCs and effector T-cell functions. DCs have now become a new molecular target for the treatment of cancer. Modified matured DCs could be novel biological modifiers to treat various diseases, including cancer. This review aims to provide an update on the impacts of various plant materials and their phytochemicals on DC-based cancer immunotherapy. Existing literature on DC-based cancer immunotherapy and plant-based pharmacological modulators has been explored over the last decade using various online databases such as Google Scholar, PubMed, Science Direct, and Scopus. Mounting evidence from preclinical and clinical findings suggests that various plants and their bioactive phytochemicals are effective in modulating the immune system and signaling pathways involved in anti-tumor immunity. Despite the prospective role of herbs in DC-based cancer immunotherapy, most of the studies are limited by either preclinical models or crude plant extracts. This review provides a useful perspective for developing potential plant-derived pharmacological modulators in DC-based cancer immunotherapy.

Related collections

Most cited references 76

Record: found
Abstract: found
Article: not found

Dendritic cells and the control of immunity.

J Banchereau, R Steinman (1998)

B and T lymphocytes are the mediators of immunity, but their function is under the control of dendritic cells. Dendritic cells in the periphery capture and process antigens, express lymphocyte co-stimulatory molecules, migrate to lymphoid organs and secrete cytokines to initiate immune responses. They not only activate lymphocytes, they also tolerize T cells to antigens that are innate to the body (self-antigens), thereby minimizing autoimmune reactions. Once a neglected cell type, dendritic cells can now be readily obtained in sufficient quantities to allow molecular and cell biological analysis. With knowledge comes the realization that these cells are a powerful tool for manipulating the immune system.

0 comments Cited 658 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Differentiation of effector CD4 T cell populations (*).

Jinfang Zhu, Hidehiro Yamane, William Paul (2010)

CD4 T cells play critical roles in mediating adaptive immunity to a variety of pathogens. They are also involved in autoimmunity, asthma, and allergic responses as well as in tumor immunity. During TCR activation in a particular cytokine milieu, naive CD4 T cells may differentiate into one of several lineages of T helper (Th) cells, including Th1, Th2, Th17, and iTreg, as defined by their pattern of cytokine production and function. In this review, we summarize the discovery, functions, and relationships among Th cells; the cytokine and signaling requirements for their development; the networks of transcription factors involved in their differentiation; the epigenetic regulation of their key cytokines and transcription factors; and human diseases involving defective CD4 T cell differentiation.

0 comments Cited 522 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Tumour necrosis factor and cancer.

Frances Balkwill (2009)

Tumour necrosis factor (TNF) is a major inflammatory cytokine that was first identified for its ability to induce rapid haemorrhagic necrosis of experimental cancers. When efforts to harness this anti-tumour activity in cancer treatments were underway, a paradoxical tumour-promoting role of TNF became apparent. Now that links between inflammation and cancer are appreciated, is TNF a target or a therapeutic in malignant disease -- or both?